Melissa B. Epperly, Chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 33,807 shares at $51.99 ($1.7M) on 2022-04-04, disclosed to the SEC on 2022-04-05.
Open-market sale of $1.7M ZNTL by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.75 | 8,094 | $395K | 23.3% |
| 2 | $48.75 | 8,094 | $395K | 23.3% |
| 3 | $49.90 | 1,303 | $65K | 3.8% |
| 4 | $49.90 | 1,303 | $65K | 3.8% |
| 5 | $50.70 | 2,818 | $143K | 8.4% |
| 6 | $50.70 | 2,818 |
| $143K |
| 8.4% |
| 7 | $51.99 | 4,512 | $235K | 13.9% |
| 8 | $51.99 | 4,512 | $235K | 13.9% |
| 9 | $52.44 | 353 | $19K | 1.1% |
| Total | $50.07 avg | 33,807 | $1.7M | 100% |
| Filing → |
| ROIV | SELL | 2026-07-01 | $610K | — | Filing → |
| ROIV | SELL | 2026-03-18 | $1.2M | — | Filing → |
| ZNTL | SELL | 2024-02-12 | $29K | — | Filing → |